GSK to buy Boston-based IDRx for $1.15 billion - MSN

GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration. Under the agreement …

$1.15
OFF

GSK To Buy Boston-based IDRx For $1.15 Billion - MSN

2 weeks from now

GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration. Under the agreement …

msn.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion - MSN

2 weeks from now

(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

msn.com

$1.15
OFF

GSK Acquiring US-Based IDRx For Up To $1.15 Billion - MSN

2 weeks from now

GSK (GSK) has agreed to acquire Boston-based IDRx for up to $1.15 billion as the British drugmaker looks to expand its gastrointestinal cancer portfolio, the companies said Monday.

msn.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion | Reuters

2 weeks from now

2 days ago · British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

reuters.com

$1.15
OFF

GSK To Buy U.S. Rare Tumor Specialist IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · GSK is buying privately-owned U.S. rare-tumor specialist IDRx for up to $1.15 billion, boosting its gastrointestinal cancer portfolio. The pharmaceutical giant said Monday that it will …

morningstar.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · British drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 billion payment. IDRx develops a treatment for …

indiatimes.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · (Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a …

investing.com

$1.15
OFF

GSK To Acquire Boston-based Biopharmaceutical Firm IDRx For Up …

2 weeks from now

2 days ago · Investing.com -- British pharmaceutical company GSK announced on Monday that it plans to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion. This move …

investing.com

$1.15
OFF

GSK To Buy US Cancer Drug Firm IDRx For Up To $1.15bn

2 weeks from now

1 day ago · GSK, Britain’s second-biggest drugmaker behind AstraZeneca, said the acquisition of IDRx, based in Plymouth near Boston, would help it target a “major gap in the current standard …

pressreader.com

$1.15
OFF

M&A Snapshot: GSK To Acquire IDRx In $1.15B Deal, Expanding In …

2 weeks from now

GSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript) GSK plc 2024 Q3 - Results - Earnings Call Presentation GSK to buy Boston-based IDRx for $1.15 billion

msn.com

$1
OFF

GSK In Talks To Buy US Biotech Company For $1bn

2 weeks from now

Jan 8, 2025 · The FTSE 100 company plans the bolt-on purchase of IDRx, a cancer drug specialist based in Cambridge, Massachusetts

thetimes.com

$1
OFF

GSK In Talks To Buy U.S. Rare Tumor Specialist IDRx For Up To $1 ...

2 weeks from now

6 days ago · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 …

morningstar.com

$1
OFF

Is GSK Prepping A $1bn Takeover Bid For IDRx? | Pharmaphorum

2 weeks from now

6 days ago · GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

pharmaphorum.com

$1
OFF

GSK Swooping To Buy US Biotech IDRx For $1bn - Report

2 weeks from now

Jan 8, 2025 · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. Backed by a raft of …

proactiveinvestors.com

$1
OFF

GSK Swooping To Buy US Biotech IDRx For $1bn - Report

2 weeks from now

Jan 8, 2025 · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. ...

proactiveinvestors.co.uk

$1
OFF

GlaxoSmithKline Plc Sponsored ADR (GSK.US) Plans To Spend $1 …

2 weeks from now

According to informed sources, GlaxoSmithKline plc Sponsored ADR (GSK.US) is in negotiations to acquire the biotechnology company IDRx, with the valuation of the latter potentially reaching …

gmteight.com

$1
OFF

GSK Nears $1 Billion Deal To Acquire IDRx For Rare ... | DeepNewz

2 weeks from now

6 days ago · GSK is nearing a $1 billion deal to acquire IDRx, a biotechnology company focused on developing a targeted therapy for a rare gastrointestinal cancer that affects between 4,000 …

deepnewz.com

FAQs about GSK to buy Boston-based IDRx for $1.15 billion - MSN Coupon?

Will GSK pay $115 billion to buy idrx?

(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour. IDRx, a privately held biotechnology firm, is developing a therapy for the treatment of gastrointestinal stromal tumours. ...

What is idrx's deal with GSK?

IDRx, a privately held biotechnology firm, is developing a therapy for the treatment of gastrointestinal stromal tumours. The deal, which comprises an upfront payment of $1 billion, will add to GSK's growing portfolio in gastrointestinal cancers. ...

Who owns idrx?

IDRx counts Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, and RA Capital Management among its investors. GSK (GSK) has agreed to acquire Boston-based IDRx for up to $1.15 billion as the British drugmaker looks to expand its gastrointestinal cancer portfolio, the companies said Monday. ...

How much does GSK pay for idrx-42?

Under the agreement signed by both companies, GSK (GSK) will pay $1 billion upfront, with the potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. ...

Why did GSK acquire idrx-42?

“IDRX-42 complements our growing portfolio in gastrointestinal cancers. This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical need, despite existing approved products.” said Luke Miels, Chief Commercial Officer, GSK. ...

Will GSK advance idrx-42 for patients with Gist?

"We are looking forward to working with GSK to advance IDRX-42 for patients with GIST given there have been no major advances to the standard of care for almost 20 years," IDRx Chief Executive Tim Clackson said. ...